论文部分内容阅读
自从明确了小剂量Ara—C 化疗常可使低增生型白血病和骨髓增生异常综合征(MDS)取得缓解以来,这一疗法已被广泛应用。这类患者由于宿主造血细胞的增殖能力低下,而小剂量Ara-C 对宿主骨髓细胞损伤小,长期给予可逐渐损害白血病细胞,使其清除。之后可见到宿主造血细胞的增殖和恢复,其机理显而易见。在实际治疗中,往往可见白细胞和血小板数量进一步减少,发热和出血一过性加重。但原始细胞则减少。停药2～3周后,血小板迅速上升,粒细胞增加,最终达到缓解。也有时可见到在短时间内,原始细胞减少,成熟粒细胞增加,而白细胞总数并不降低。加之在体外用来自肿瘤的细胞株进行培养,加入低徙度的Ara—C 时,短期内可见到成熟型细胞的出现。因此,推测低浓度的Ara—C 诱导了肿瘤细胞
This therapy has been widely used since it has been established that low-dose Ara-C chemotherapy often leads to the relief of hypo-proliferative leukemia and myelodysplastic syndromes (MDS). Such patients due to poor proliferation of host hematopoietic cells, and low doses of Ara-C on the host bone marrow cell damage is small, long-term administration can gradually damage leukemia cells to make it clear. After the proliferation of host hematopoietic cells and recovery can be seen, the mechanism is obvious. In actual treatment, white blood cells and platelets can often be seen to further reduce the number of fever and bleeding a transient increase. However, the number of primitive cells is reduced. After 2 to 3 weeks of withdrawal, platelets rapidly increase and granulocytes increase, eventually achieving remission. Sometimes also seen in a short time, primitive cells decreased, mature granulocytes increased, while the total number of leukocytes is not reduced. In addition, in vitro culture from tumor-bearing cell lines, adding low-density Ara-C, the appearance of mature cells can be seen in the short term. Therefore, it is speculated that low concentrations of Ara-C induce tumor cells